22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

ADI-PEG 20: Phase Ib data

Top-line data from an open-label, U.S. Phase Ib trial in 18 patients with metastatic pancreatic cancer showed that once-weekly intramuscular ADI-PEG 20 plus gemcitabine and Abraxane nab-paclitaxel led to a disease control rate (DCR) of...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

ADI-PEG 20: Phase I started

Polaris began an open-label, U.S. Phase I trial to evaluate ADI-PEG 20 in combination with FOLFOX chemotherapy in about 22 patients. Polaris Pharmaceuticals Inc. , San Diego, Calif.   Product: ADI-PEG 20   Business: Cancer...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

ADI-PEG 20: Phase I started

Polaris began an open-label, U.S. Phase I trial to evaluate ADI-PEG 20 in combination with Nexavar sorafenib in about 21 patients. The compound is in Phase III testing as monotherapy for HCC. Polaris Pharmaceuticals Inc....
08:00 , Dec 22, 2014 |  BC Week In Review  |  Clinical News

ADI-PEG 20: Phase Ib started

Polaris began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate intramuscular ADI-PEG 20 plus Abraxane nab-paclitaxel and gemcitabine in about 21 patients. The maximum tolerated dose (MTD) will be tested in an expansion cohort....
07:00 , Apr 28, 2014 |  BioCentury  |  Emerging Company Profile

Aeglea: Old enzymes, new tricks

Aeglea BioTherapeutics Holdings LLC is developing enzymes to starve tumors that depend on outside sources of specific amino acids. Aeglea's engineered human enzymes may offer lower immunogenicity and greater activity than natural versions further along...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

ADI-PEG 20: Phase II started

Polaris began an open-label Phase II trial to evaluate ADI-PEG 20 in about 21 patients with relapsed and/or refractory AML. ADI-PEG 20 is in a Phase III trial under an SPA from FDA to treat...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

ADI-PEG 20: Phase II data

The open-label, U.K. Phase II ADAM trial in 68 patients with MPM showed that once-weekly 36.8 mg/m 2 intramuscular ADI-PEG 20 plus best supportive care (BSC) for 6 months met the primary endpoint of improving...
00:46 , Oct 29, 2013 |  BC Extra  |  Clinical News

Polaris' ADI-PEG 20 meets in Phase II mesothelioma trial

Polaris Pharmaceuticals Inc. (San Diego, Calif.) said once-weekly intramuscular ADI-PEG 20 plus best supportive care (BSC) for six months met the primary endpoint of improving median progression-free survival (PFS) vs. BSC alone in the Phase...
07:00 , Apr 26, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Phosphoinositide 3-kinase (PI3K) Mouse and cell culture studies suggest inhibiting PI3K signaling could help improve the effects of ADI-PEG 20...